Dyadic Applied BioSolutions
Business Services · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1044 N US Highway 1 Ste 201, Jupiter, Fl...Phone Number
(561) 743-8333Website
www.dyadic.comRevenue
<$5 MillionStock Symbol
DYAIIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Dyadic Applied BioSolutions
Dyadic International is a global biotechnology company developing and leveraging its proprietary C1 protein expression system to accelerate the development and production of biologic vaccines and drugs. Its technology enables drug developers and manufacturers to produce biologics in greater volumes, at lower costs, and with improved properties.Explore more
Dyadic Applied BioSolutions Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dyadic Applied BioSolutions your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Dyadic Applied BioSolutions had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Dyadic Applied BioSolutions has new funding data
Dyadic Applied BioSolutions, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Dyadic Applied BioSolutions launches new products
Congratulate Masked Content for being promoted to Masked Content at Dyadic Applied BioSolutions
Check if Dyadic Applied BioSolutions has recently received funding, and reach out quickly before it becomes old news!
Check out if Dyadic Applied BioSolutions is spiking on competitors!
Earning: See what the market has to say on Dyadic Applied BioSolutions recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Dyadic Applied BioSolutions
Find 2 more new buyers
Compare Similar Companies to Dyadic Applied BioSolutions
Compare insights from companies similar to Dyadic Applied BioSolutions, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Dyadic Applied BioSolutions is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Dyadic Applied BioSolutions is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Dyadic Applied BioSolutions.
Dyadic Applied BioSolutions financials insights
Gather financial insights about Dyadic Applied BioSolutions, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2026
Stock/Share Issuance
$2.9M
Dyadic Applied BioSolutions Tech Stack
A closer look at the technologies used by Dyadic Applied BioSolutions
Most Recent Scoops
Project
Dyadic Applied BioSolutions has completed a Phase 1 study demonstrating that a protein produced on its C1 platform is safe for administration to human beings, validating the platform's capability to express human therapeutics with high productivity and low-cost production.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Dyadic Applied BioSolutions has announced a life sciences cell culture media pipeline comprising albumin, transferrin, growth factors, human alpha-lactalbumin, bovine alpha-lactalbumin, and DNase-1, with early pilot sales of human transferrin and human growth factors underway and multiple products targeted for commercialization in 2026, serving cell culture media, cell and gene therapy, diagnostics, and reagents markets.
Product Development, Product Launch
Project
Dyadic Applied BioSolutions has developed an Ebola vaccine antigen in collaboration with the Scripps Institute and is advancing an Ebola monoclonal antibody, both currently in preclinical development, with animal studies potentially commencing later this year or in early 2026.
Medical Research, Pharmaceuticals
Project
Research & Development
Dyadic Applied BioSolutions News & Media
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private PlacementDyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript
Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call August 12, 2026 5:00 PM EDTCompany ParticipantsPing Rawson - Chief Financial OfficerJoseph Hazelton...Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business AreasDyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Dyadic Applied BioSolutions
Sign Up For FreeTo access detailed company insights
Dyadic International is a global biotechnology company developing and leveraging its proprietary C1 protein expression system to accelerate the development and production of biologic vaccines and drugs. Its technology enables drug developers and manufacturers to produce biologics in greater volumes, at lower costs, and with improved properties.... Read More
